{
    "nctId": "NCT01082211",
    "briefTitle": "Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery",
    "officialTitle": "A Phase II Study of Repeat Breast Preserving Surgery and 3D-Conformal Partial Breast Re-Irradiation (PBrI) for Local Recurrence of Breast Carcinoma",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 65,
    "primaryOutcomeMeasure": "Number of Participants With Grade 3+ Treatment-related Skin, Fibrosis, and Breast Pain Adverse Events",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed locally recurrent breast carcinoma consistent with the following cell types:\n\n  * Invasive ductal breast carcinoma\n  * Medullary ductal breast carcinoma\n  * Tubular ductal breast carcinoma\n  * Mucinous ductal breast carcinoma\n  * Lobular breast carcinoma\n  * Ductal carcinoma in situ (DCIS)\n\n    * No Paget disease of the nipple\n  * Target lumpectomy cavity must be clearly defined and the target lumpectomy cavity/ whole-breast reference volume must be \\< 30% based on a post-operative, pre-treatment CT scan\n  * Tumor size \u2264 3 cm in greatest dimension on pathologic specimen\n  * Negative histologic margins of resection and no tumor on ink following breast-preserving surgery of local recurrence (Re-excision is permitted to achieve negative margins)\n  * Axilla negative or \u2264 3 positive lymph nodes without extracapsular extension\n  * If the in-breast recurrence is DCIS and/or microinvasive disease, a sentinel lymph node (SLN) evaluation is not required, but if performed:\n  * Patients with a negative sentinal lymph node (SLN) biopsy are eligible for enrollment\n  * Patients with a positive SLN biopsy require an axillary lymph node (ALN) dissection (ALND is not required if the SLN is not identified)\n  * Patient is eligible if 0-3 positive ALNs without extracapsular extension is documented\n* If the in-breast recurrence is invasive disease and:\n\n  * No prior ALN dissection or SLN dissection only:\n\n    * Patient is required to undergo axillary evaluation with either a SLN or ALN dissection\n    * If the SLN is not identified or if the SLN is positive for metastatic disease then an ALN dissection is required\n    * Patient is eligible for enrollment if encounter 0-3 positive lymph nodes without extracapsular extension\n  * \u2022 Prior ALN dissection: negative clinical exam: patient is eligible for enrollment\n\n    * It is recommended, but not required, that the patient undergo ultrasound evaluation of the axilla and the lymph node draining regions of the breast; any suspicious areas are to be biopsied and if positive followed with an ALN dissection\n    * Patient is eligible for enrollment if biopsies are negative or 0-3 axillary lymph nodes without extracapsular extension are encountered\n  * Prior ALN dissection: positive clinical exam: biopsy required\n\n    * If biopsy is negative, patient is eligible for enrollment\n    * If biopsy is positive an ALN dissection is required\n    * Patient is eligible for enrollment if biopsies are negative or 0-3 axillary lymph nodes without extracapsular extension encountered\n* Ipsilateral breast mammogram and MRI within 120 days prior to study entry\n* Contralateral breast mammogram within 12 months of study entry\n* For invasive in-breast recurrence, no more than 120 days since whole-body (positron emission tomography) PET-CT scan OR CT scan of the chest, abdomen, and pelvis, and bone scan\n* No multicentric ipsilateral breast recurrence or regional recurrence (other than axilla)\n* Patients must have a breast technically amenable to partial-breast irradiation\n* No metastatic disease documented by physical exam or radiographic evaluation (for patients with invasive disease)\n* No skin involvement\n* No prior contralateral mastectomy\n* Estrogen and progesterone status must be known\n\nPATIENT CHARACTERISTICS:\n\n* Zubrod performance status 0-1\n* Menopausal status not specified\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No other invasive malignancy within the past 3 years except ipsilateral breast cancer and/or nonmelanoma skin cancer\n* No collagenous diseases, specifically systemic lupus erythematosus, scleroderma, or dermatomyositis\n* No psychiatric or addictive disorders that would preclude obtaining informed consent\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* More than 2 weeks since prior chemotherapy and recovered\n* No concurrent intensity-modulated radiotherapy\n* No concurrent chemotherapeutic agents, including trastuzumab",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}